Booster shot could boost supply of lifesaving infant botulism treatment
NCT ID NCT06112834
First seen Jun 24, 2026 · Last updated Jul 31, 2026 · Updated 3 times
Summary
This study tested a single booster dose of a recombinant botulinum vaccine in 25 healthy adults who had already been vaccinated against botulism for work. The goal was to see if the booster safely raises their antibody levels enough to donate plasma for making BabyBIG, a treatment for infant botulism. Participants were followed for 12 weeks, with a safety check at 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Recombinant Botulinum Vaccine A/B (rBV A/B)
- What this could lead to
- If successful, this could help produce more BabyBIG, a life-saving treatment for infant botulism, by boosting antibody levels in donors.
- What could go wrong
- This is a small, early-phase study with only 25 participants, so results may not apply broadly. The vaccine is given to already-immunized people, not tested as a new prevention method.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BOTULISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Battelle Biomedical Research Center
West Jefferson, Ohio, 43162, United States
-
California Department of Public Health
Richmond, California, 94804, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.